在沙尔科毒症中,渐进性多焦点性白细胞大脑病变成功地用 pembrolizumab 治疗
Gizem Öztürk1, Elif İrem Tekeli2, Seyda Erdoğan2
1Department of Neurology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, 06230, Türkiye. ozturkgizem96@gmail.com.
Journal of neurovirology
|August 18, 2024
概括
渐进性多焦点白内障 (PML),一种大脑疾病,在接受 pembrolizumab (PD-1 抑制剂) 治疗的肉类症患者中显著改善. 这表明免疫检查点抑制剂可能是潜在的PML治疗型硬化症.
科学领域:
- 神经免疫学 神经免疫学
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- 渐进性多焦点白内障 (PML) 是一种罕见的,严重的中枢神经系统脱髓化疾病,由JC病毒引起.
- PML可以发生在肉类发病患者中,即使没有其他已知的免疫抑制风险因素.
研究的目的:
- 报告一例PML病例,该病例是继发于用 pembrolizumab 治疗的沙丘病.
- 评估这种治疗的临床和放射性结果.
主要方法:
- 一名患有沙尔科毒症相关的PML的患者接受了8剂庞布罗利祖马布,这是一个编程细胞死亡-1 (PD-1) 免疫检查点抑制剂.
- 进行了临床和放射性评估,以监测疾病进展和治疗反应.
主要成果:
- 患者表现出显著的临床改善.
- 放射性成像证实了脱髓化病变的减少,表明疾病有所改善.
结论:
- 布罗利祖马布治疗导致了一名患有沙尔科毒症相关的PML的患者客观临床和放射性改善.
- 免疫检查点抑制剂需要进一步研究,作为在沙尔科毒症患者中治疗PML的潜在治疗策略.
相关概念视频
01:15Parkinson's Disease: Overview
501
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
01:24Parkinson's Disease: Treatment
240
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240